1
|
Dionisio-Santos DA, Karaahmet B, Belcher EK, Owlett LD, Trojanczyk LA, Olschowka JA, O'Banion MK. Evaluating Effects of Glatiramer Acetate Treatment on Amyloid Deposition and Tau Phosphorylation in the 3xTg Mouse Model of Alzheimer's Disease. Front Neurosci 2021; 15:758677. [PMID: 34744620 PMCID: PMC8569891 DOI: 10.3389/fnins.2021.758677] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2021] [Accepted: 09/28/2021] [Indexed: 12/22/2022] Open
Abstract
Neuroinflammation driven by the accumulation of amyloid β (Aβ) can lead to neurofibrillary tangle formation in Alzheimer's Disease (AD). To test the hypothesis that an anti-inflammatory immunomodulatory agent might have beneficial effects on amyloid and tau pathology, as well as microglial phenotype, we evaluated glatiramer acetate (GA), a multiple sclerosis drug thought to bias type 2 helper T (Th2) cell responses and alternatively activate myeloid cells. We administered weekly subcutaneous injections of GA or PBS to 15-month-old 3xTg AD mice, which develop both amyloid and tau pathology, for a period of 8 weeks. We found that subcutaneous administration of GA improved behavioral performance in novel object recognition and decreased Aβ plaque in the 3xTg AD mice. Changes in tau phosphorylation were mixed with specific changes in phosphoepitopes seen in immunohistochemistry but not observed in western blot. In addition, we found that there was a trend toward increased microglia complexity in 3xTg mice treated with GA, suggesting a shift toward homeostasis. These findings correlated with subtle changes in the microglial transcriptome, in which the most striking difference was the upregulation of Dcstamp. Lastly, we found no evidence of changes in proportions of major helper T cell (Th) subtypes in the periphery. Overall, our study provides further evidence for the benefits of immunomodulatory therapies that alter the adaptive immune system with the goal of modifying microglia responses for the treatment of Alzheimer's Disease.
Collapse
Affiliation(s)
- Dawling A Dionisio-Santos
- Department of Neuroscience, School of Medicine and Dentistry, Del Monte Neuroscience Institute, University of Rochester, Rochester, NY, United States
| | - Berke Karaahmet
- Department of Neuroscience, School of Medicine and Dentistry, Del Monte Neuroscience Institute, University of Rochester, Rochester, NY, United States
| | - Elizabeth K Belcher
- Department of Neuroscience, School of Medicine and Dentistry, Del Monte Neuroscience Institute, University of Rochester, Rochester, NY, United States
| | - Laura D Owlett
- Department of Neuroscience, School of Medicine and Dentistry, Del Monte Neuroscience Institute, University of Rochester, Rochester, NY, United States
| | - Lee A Trojanczyk
- Department of Neuroscience, School of Medicine and Dentistry, Del Monte Neuroscience Institute, University of Rochester, Rochester, NY, United States
| | - John A Olschowka
- Department of Neuroscience, School of Medicine and Dentistry, Del Monte Neuroscience Institute, University of Rochester, Rochester, NY, United States
| | - M Kerry O'Banion
- Department of Neuroscience, School of Medicine and Dentistry, Del Monte Neuroscience Institute, University of Rochester, Rochester, NY, United States
| |
Collapse
|
2
|
Owlett L, Belcher EK, Dionisio-Santos DA, Williams JP, Olschowka JA, O'Banion MK. Space radiation does not alter amyloid or tau pathology in the 3xTg mouse model of Alzheimer's disease. Life Sci Space Res (Amst) 2020; 27:89-98. [PMID: 34756235 DOI: 10.1016/j.lssr.2020.08.001] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/09/2020] [Revised: 07/25/2020] [Accepted: 08/02/2020] [Indexed: 05/27/2023]
Abstract
Space radiation is comprised of highly charged ions (HZE particles) and protons that are able to pass through matter and cause radiation-induced injury, including neuronal damage and degeneration, glial activation, and oxidative stress. Previous work demonstrated a worsening of Alzheimer's disease pathology in the APP/PS1 transgenic mouse model, however effects of space radiation on tau pathology have not been studied. To determine whether tau pathology is altered by HZE particle or proton irradiation, we exposed 3xTg mice, which acquire both amyloid plaque and tau pathology with age, to iron, silicon, or solar particle event (SPE) irradiation at 9 months of age and evaluated behavior and brain pathology at 16 months of age. We found no differences in performance in fear conditioning and novel object recognition tasks between groups of mice exposed to sham, iron (10 and 100 cGy), silicon (10 and 100 cGy), or solar particle event radiation (200 cGy), though female mice had higher freezing responses than males. 200 cGy SPE irradiated female mice had fewer plaques than sham-irradiated females but had no differences in tau pathology. Overall, females had worse amyloid and tau pathology at 16 months of age and demonstrated a reduced neuroinflammatory gene expression response to radiation. These findings uncover differences between mouse models following radiation injury and corroborate prior reports of sex differences within the 3xTg mouse model.
Collapse
Affiliation(s)
- Laura Owlett
- Department of Neuroscience, University of Rochester Medical Center, 601 Elmwood Ave, Box 603, Rochester, NY, 14642, USA
| | - Elizabeth K Belcher
- Department of Neuroscience, University of Rochester Medical Center, 601 Elmwood Ave, Box 603, Rochester, NY, 14642, USA
| | - Dawling A Dionisio-Santos
- Department of Neuroscience, University of Rochester Medical Center, 601 Elmwood Ave, Box 603, Rochester, NY, 14642, USA
| | - Jacqueline P Williams
- Department of Environmental Medicine, University of Rochester Medical Center, 601 Elmwood Ave, Box EHSC, Rochester, NY, 14642, USA
| | - John A Olschowka
- Department of Neuroscience, University of Rochester Medical Center, 601 Elmwood Ave, Box 603, Rochester, NY, 14642, USA; Del Monte Neuroscience Institute, University of Rochester Medical Center, 601 Elmwood Ave, Box 603, Rochester, NY, 14642, USA
| | - M Kerry O'Banion
- Department of Neuroscience, University of Rochester Medical Center, 601 Elmwood Ave, Box 603, Rochester, NY, 14642, USA; Del Monte Neuroscience Institute, University of Rochester Medical Center, 601 Elmwood Ave, Box 603, Rochester, NY, 14642, USA; Department of Neurology, University of Rochester Medical Center, 601 Elmwood Ave, Box 673, Rochester, NY, 14642, USA.
| |
Collapse
|
3
|
Simpkins AN, Busl KM, Amorim E, Barnett-Tapia C, Cervenka MC, Dhakar MB, Etherton MR, Fung C, Griggs R, Holloway RG, Kelly AG, Khan IR, Lizarraga KJ, Madagan HG, Onweni CL, Mestre H, Rabinstein AA, Rubinos C, Dionisio-Santos DA, Youn TS, Merck LH, Maciel CB. Proceedings from the Neurotherapeutics Symposium on Neurological Emergencies: Shaping the Future of Neurocritical Care. Neurocrit Care 2020; 33:636-645. [PMID: 32959201 PMCID: PMC7736003 DOI: 10.1007/s12028-020-01085-0] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2020] [Accepted: 08/19/2020] [Indexed: 12/11/2022]
Abstract
Effective treatment options for patients with life-threatening neurological disorders are limited. To address this unmet need, high-impact translational research is essential for the advancement and development of novel therapeutic approaches in neurocritical care. "The Neurotherapeutics Symposium 2019-Neurological Emergencies" conference, held in Rochester, New York, in June 2019, was designed to accelerate translation of neurocritical care research via transdisciplinary team science and diversity enhancement. Diversity excellence in the neuroscience workforce brings innovative and creative perspectives, and team science broadens the scientific approach by incorporating views from multiple stakeholders. Both are essential components needed to address complex scientific questions. Under represented minorities and women were involved in the organization of the conference and accounted for 30-40% of speakers, moderators, and attendees. Participants represented a diverse group of stakeholders committed to translational research. Topics discussed at the conference included acute ischemic and hemorrhagic strokes, neurogenic respiratory dysregulation, seizures and status epilepticus, brain telemetry, neuroprognostication, disorders of consciousness, and multimodal monitoring. In these proceedings, we summarize the topics covered at the conference and suggest the groundwork for future high-yield research in neurologic emergencies.
Collapse
Affiliation(s)
- Alexis N Simpkins
- Department of Neurology, McKnight Brain Institute, University of Florida College of Medicine, Room L3-100, 1149 Newell Drive, Gainesville, FL, 32611, USA.
| | - Katharina M Busl
- Department of Neurology, McKnight Brain Institute, University of Florida College of Medicine, Room L3-100, 1149 Newell Drive, Gainesville, FL, 32611, USA
- Department of Neurosurgery, University of Florida College of Medicine, Gainesville, FL, USA
| | - Edilberto Amorim
- Department of Neurology, University of California, San Francisco, San Francisco, CA, USA
| | - Carolina Barnett-Tapia
- Ellen and Martin Prosserman Centre for Neuromuscular Disorders, Toronto General Hospital, Toronto, ON, Canada
| | - Mackenzie C Cervenka
- Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
| | - Monica B Dhakar
- Department of Neurology, Emory University School of Medicine, Atlanta, GA, USA
- Department of Neurology, Yale University School of Medicine, New Haven, CT, USA
| | - Mark R Etherton
- J. Phillip Kistler Stroke Research Center, Massachusetts General Hospital, Boston, MA, USA
| | - Celia Fung
- Department of Neurology, University of Rochester Medical Center, Rochester, NY, USA
| | - Robert Griggs
- Department of Neurology, University of Rochester Medical Center, Rochester, NY, USA
| | - Robert G Holloway
- Department of Neurology, University of Rochester Medical Center, Rochester, NY, USA
| | - Adam G Kelly
- Department of Neurology, University of Rochester Medical Center, Rochester, NY, USA
| | - Imad R Khan
- Department of Neurology, University of Rochester Medical Center, Rochester, NY, USA
| | - Karlo J Lizarraga
- Department of Neurology, University of Rochester Medical Center, Rochester, NY, USA
| | - Hannah G Madagan
- Department of Neurology, McKnight Brain Institute, University of Florida College of Medicine, Room L3-100, 1149 Newell Drive, Gainesville, FL, 32611, USA
| | - Chidinma L Onweni
- Department of Critical Care Medicine, Mayo Clinic, Jacksonville, FL, USA
| | - Humberto Mestre
- Center for Translational Neuromedicine, Department of Neurosurgery, University of Rochester Medical Center, Rochester, USA
| | | | - Clio Rubinos
- Department of Neurology, University of North Carolina School of Medicine, Chapel Hill, NC, USA
| | | | - Teddy S Youn
- Department of Neurology, Barrow Neurological Institute, Phoenix, AZ, USA
| | - Lisa H Merck
- Department of Emergency Medicine, University of Florida College of Medicine, Gainesville, FL, USA
- Department of Health Outcomes and Biomedical Informatics, University of Florida College of Medicine, Gainesville, FL, USA
| | - Carolina B Maciel
- Department of Neurology, McKnight Brain Institute, University of Florida College of Medicine, Room L3-100, 1149 Newell Drive, Gainesville, FL, 32611, USA
- Department of Neurosurgery, University of Florida College of Medicine, Gainesville, FL, USA
- Department of Neurology, Yale University School of Medicine, New Haven, CT, USA
- Department of Neurology, University of Utah, Salt Lake City, UT, USA
| |
Collapse
|
4
|
Dionisio-Santos DA, Behrouzi A, Olschowka JA, O'Banion MK. Evaluating the Effect of Interleukin-4 in the 3xTg Mouse Model of Alzheimer's Disease. Front Neurosci 2020; 14:441. [PMID: 32528242 PMCID: PMC7247853 DOI: 10.3389/fnins.2020.00441] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2020] [Accepted: 04/09/2020] [Indexed: 11/13/2022] Open
Abstract
Chronic neuroinflammation has long been hypothesized to be involved in Alzheimer's Disease (AD) progression. Previous research suggests that both anti-inflammatory and inflammatory microglia ameliorate amyloid pathology, but the latter worsen tau pathology. In this study, we sought to determine whether induction of arginase-1 positive microglia with the anti-inflammatory cytokine IL-4 modulates pathology in the 3xTg mouse model of AD. Our findings indicate that a single intracranial IL-4 injection positively modulated performance of 3xTg AD mice in a Novel Object Recognition task, and locally increased the levels of arginase-1 positive myeloid cells when assessed one-week post injection. Furthermore, immunohistochemical analysis revealed decreased tau phosphorylation in IL-4 injected animals; however, we were not able to detect significant changes in tau phosphorylation utilizing Western blot. Lastly, IL-4 injection did not appear to cause significant changes in amyloid β load. In conclusion, acute intracranial IL-4 led to some positive benefits in the 3xTg mouse model of AD. Although more work remains, these results support therapeutic strategies aimed at modifying microglial activation states in neurodegenerative diseases.
Collapse
Affiliation(s)
- Dawling A Dionisio-Santos
- Department of Neuroscience, Del Monte Institute for Neuroscience, University of Rochester School of Medicine and Dentistry, Rochester, NY, United States
| | - Adib Behrouzi
- Department of Neuroscience, Del Monte Institute for Neuroscience, University of Rochester School of Medicine and Dentistry, Rochester, NY, United States
| | - John A Olschowka
- Department of Neuroscience, Del Monte Institute for Neuroscience, University of Rochester School of Medicine and Dentistry, Rochester, NY, United States
| | - M Kerry O'Banion
- Department of Neuroscience, Del Monte Institute for Neuroscience, University of Rochester School of Medicine and Dentistry, Rochester, NY, United States
| |
Collapse
|
5
|
Dionisio-Santos DA, Olschowka JA, O'Banion MK. Exploiting microglial and peripheral immune cell crosstalk to treat Alzheimer's disease. J Neuroinflammation 2019; 16:74. [PMID: 30953557 PMCID: PMC6449993 DOI: 10.1186/s12974-019-1453-0] [Citation(s) in RCA: 108] [Impact Index Per Article: 21.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2019] [Accepted: 03/18/2019] [Indexed: 12/21/2022] Open
Abstract
Neuroinflammation is considered one of the cardinal features of Alzheimer’s disease (AD). Neuritic plaques composed of amyloid β and neurofibrillary tangle-laden neurons are surrounded by reactive astrocytes and microglia. Exposure of microglia, the resident myeloid cell of the CNS, to amyloid β causes these cells to acquire an inflammatory phenotype. While these reactive microglia are important to contain and phagocytose amyloid plaques, their activated phenotype impacts CNS homeostasis. In rodent models, increased neuroinflammation promoted by overexpression of proinflammatory cytokines can cause an increase in hyperphosphorylated tau and a decrease in hippocampal function. The peripheral immune system can also play a detrimental or beneficial role in CNS inflammation. Systemic inflammation can increase the risk of developing AD dementia, and chemokines released directly by microglia or indirectly by endothelial cells can attract monocytes and T lymphocytes to the CNS. These peripheral immune cells can aid in amyloid β clearance or modulate microglia responses, depending on the cell type. As such, several groups have targeted the peripheral immune system to modulate chronic neuroinflammation. In this review, we focus on the interplay of immunomodulating factors and cell types that are being investigated as possible therapeutic targets for the treatment or prevention of AD.
Collapse
Affiliation(s)
- Dawling A Dionisio-Santos
- Department of Neuroscience, Del Monte Institute for Neuroscience, University of Rochester School of Medicine and Dentistry, 601 Elmwood Avenue, Box 603, Rochester, NY, 14642, USA
| | - John A Olschowka
- Department of Neuroscience, Del Monte Institute for Neuroscience, University of Rochester School of Medicine and Dentistry, 601 Elmwood Avenue, Box 603, Rochester, NY, 14642, USA
| | - M Kerry O'Banion
- Department of Neuroscience, Del Monte Institute for Neuroscience, University of Rochester School of Medicine and Dentistry, 601 Elmwood Avenue, Box 603, Rochester, NY, 14642, USA.
| |
Collapse
|
6
|
Dionisio-Santos DA. The Flying Bus. J Med Humanit 2015; 36:399-400. [PMID: 26337180 DOI: 10.1007/s10912-015-9356-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Affiliation(s)
- Dawling A Dionisio-Santos
- Medical Scientist Training Program, University of Rochester School of Medicine and Dentistry, Rochester, NY, United States.
| |
Collapse
|